Cargando…

Targeting Hypoxia: Revival of Old Remedies

Tumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Vilaplana-Lopera, Nuria, Besh, Maxym, Moon, Eui Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615589/
https://www.ncbi.nlm.nih.gov/pubmed/34827602
http://dx.doi.org/10.3390/biom11111604
_version_ 1784604140877381632
author Vilaplana-Lopera, Nuria
Besh, Maxym
Moon, Eui Jung
author_facet Vilaplana-Lopera, Nuria
Besh, Maxym
Moon, Eui Jung
author_sort Vilaplana-Lopera, Nuria
collection PubMed
description Tumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find specific treatments for tumour hypoxia. In this review, we discuss a variety of approaches to alter the low oxygen tumour microenvironment or hypoxia pathways including carbogen breathing, hyperthermia, hypoxia-activated prodrugs, tumour metabolism and hypoxia-inducible factor (HIF) inhibitors. The recent advances in technology and biological understanding reveal the importance of revisiting old therapeutic regimens and repurposing their uses clinically.
format Online
Article
Text
id pubmed-8615589
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86155892021-11-26 Targeting Hypoxia: Revival of Old Remedies Vilaplana-Lopera, Nuria Besh, Maxym Moon, Eui Jung Biomolecules Review Tumour hypoxia is significantly correlated with patient survival and treatment outcomes. At the molecular level, hypoxia is a major driving factor for tumour progression and aggressiveness. Despite the accumulative scientific and clinical efforts to target hypoxia, there is still a need to find specific treatments for tumour hypoxia. In this review, we discuss a variety of approaches to alter the low oxygen tumour microenvironment or hypoxia pathways including carbogen breathing, hyperthermia, hypoxia-activated prodrugs, tumour metabolism and hypoxia-inducible factor (HIF) inhibitors. The recent advances in technology and biological understanding reveal the importance of revisiting old therapeutic regimens and repurposing their uses clinically. MDPI 2021-10-29 /pmc/articles/PMC8615589/ /pubmed/34827602 http://dx.doi.org/10.3390/biom11111604 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vilaplana-Lopera, Nuria
Besh, Maxym
Moon, Eui Jung
Targeting Hypoxia: Revival of Old Remedies
title Targeting Hypoxia: Revival of Old Remedies
title_full Targeting Hypoxia: Revival of Old Remedies
title_fullStr Targeting Hypoxia: Revival of Old Remedies
title_full_unstemmed Targeting Hypoxia: Revival of Old Remedies
title_short Targeting Hypoxia: Revival of Old Remedies
title_sort targeting hypoxia: revival of old remedies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8615589/
https://www.ncbi.nlm.nih.gov/pubmed/34827602
http://dx.doi.org/10.3390/biom11111604
work_keys_str_mv AT vilaplanaloperanuria targetinghypoxiarevivalofoldremedies
AT beshmaxym targetinghypoxiarevivalofoldremedies
AT mooneuijung targetinghypoxiarevivalofoldremedies